Journal article
The Relation of Virologic and Immunologic Markers to Clinical Outcomes after Nucleoside Therapy in HIV-Infected Adults with 200 to 500 CD4 Cells per Cubic Millimeter
The New England journal of medicine, Vol.335(15), pp.1091-1098
10/10/1996
DOI: 10.1056/NEJM199610103351502
PMID: 8813039
Abstract
The AIDS Clinical Trials Group Study 175 (ACTG 175) provides direct evidence, in the clinical report elsewhere in this issue of the
Journal,
1
of the clinical and immunologic benefits (e.g., increased CD4 cell counts) of the treatment of human immunodeficiency virus (HIV) infection with didanosine, zidovudine plus didanosine, and zidovudine plus zalcitabine, as compared with zidovudine monotherapy. Although changes in CD4 cell counts have provided a basis for the initiation of antiretroviral treatment and have been used to help define the acquired immunodeficiency syndrome (AIDS),
2
the plasma HIV RNA concentration is increasingly used as a measure of viral replication in . . .
Details
- Title: Subtitle
- The Relation of Virologic and Immunologic Markers to Clinical Outcomes after Nucleoside Therapy in HIV-Infected Adults with 200 to 500 CD4 Cells per Cubic Millimeter
- Creators
- David A KatzensteinScott M HammerMichael D HughesHolly GundackerJ. Brooks JacksonSusan FiscusSuraiya RasheedTarek ElbeikRichard ReichmanAnthony JapourThomas C MeriganMartin S Hirsch
- Resource Type
- Journal article
- Publication Details
- The New England journal of medicine, Vol.335(15), pp.1091-1098
- DOI
- 10.1056/NEJM199610103351502
- PMID
- 8813039
- NLM abbreviation
- N Engl J Med
- ISSN
- 0028-4793
- eISSN
- 1533-4406
- Publisher
- Massachusetts Medical Society
- Language
- English
- Date published
- 10/10/1996
- Academic Unit
- Pathology; VPMA - Administration
- Record Identifier
- 9984047976002771
Metrics
21 Record Views